Abstract:Objective: Currently there is no cure for cystic fibrosis (CF) disease and lung is the most affected organ [1Cooney A Gene. 2018 Nov; 9: 538Crossref Scopus (72) Google Scholar]. Gene replacement is a promising strategy to treat this disease. However, the two big challenges that have impeded its success are the absence of: (1) an efficient and safe gene delivery reagent to transfect the target cells, and (2) a stable plasmid that enables high and sustained CF transmembrane conductance regulator (CFTR) expression. Thus, the aim of this work is to develop a non-viral CFTR gene replacement system for lung CF disease to overcome these two challenges. Methods: A cationic highly branched poly(β-amino ester) (HPAE) polymer [2Zhou D Sci Adv. 2016 Jun; 6e160010Google Scholar] with high transfection efficiency was used as a non-viral gene delivery reagent complexed to a CpG-depleted CFTR plasmid with high and sustained CFTR expression and expected lower immune response to transfect CF lung epithelial cells in vitro. Results: By using the HPAE for CFTR gene delivery, similar gene expression and higher cell viability (~98%) than commercial transfection reagents such as Xfect™ (~77%) and Lipofectamine™ 3000 (~51%) were achieved after 48 hours. Moreover, around 2400% and 120% higher CFTR protein levels compared to healthy human lung epithelial cells were obtained after 48 hours and 7 days of transfection in CF lung epithelial cells, respectively. Conclusion: We developed a very promising HPAE/CFTR polyplex system as it is demonstrated that only 6–10% CFTR protein expression of healthy lung epithelial cells is enough to restore the ionic transport in CF lung epithelial cells [3Johnson L Nat Genet. 1992 Sep; 2: 21-25Crossref PubMed Scopus (382) Google Scholar]. In addition, a nebulization system for testing this HPAE/CFTR polyplex system in vivo by inhalation in mice is being currently developed. The expected results could potentially support the future use of this technology as a gene therapy for treating lung cystic fibrosis disease.

An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer.

WS17.04 Developing a Non-Viral Gene Therapy Strategy for Treating Lung Cystic Fibrosis Disease

Advanced Therapies for Congenital Biliary Tract Malformation: from Bench to Bedside

Highly Branched Poly Β-Amino Ester/cpg-Depleted CFTR Plasmid Nanoparticles for Non-viral Gene Therapy in Lung Cystic Fibrosis Disease

Correction of the Ion Transport Defect in Cystic Fibrosis Transgenic Mice by Gene Therapy

Increased Expression of Cystic Fibrosis Transmembrane Conductance Regulator in Rat Liver after Common Bile Duct Ligation

Gene therapy for cystic fibrosis: Challenges and prospects

Current landscape of cystic fibrosis gene therapy

Gene Therapy for Cystic Fibrosis Lung Disease: Overcoming the Barriers to Translation to the Clinic

Hepatobiliary Disease in Cystic Fibrosis

Therapeutic liver cell transplantation to treat a genetic liver defect

Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer

Combined heterotopic liver-pancreas transplantation as a curative treatment for liver cirrhosis and diabetes mellitus in cystic fibrosis

Efficient expansion and CRISPR-Cas9-mediated gene correction of patient-derived hepatocytes for treatment of inherited liver diseases

Lentiviral vectors for gene therapy of cystic fibrosis

Pathophysiology of Cystic Fibrosis Liver Disease

Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-In-Human Trial

Advances in the Cystic Fibrosis Drug Development Pipeline

Gene therapy vector for cystic fibrosis

Targeting CFTR restoring aggrephagy to suppress HSC activation and alleviate liver fibrosis

Current Status and Future Directions of Gene and Cell Therapy for Cystic Fibrosis